Cytokinetics says UK MHRA approves MYQORZO for obstructive hypertrophic cardiomyopathy

Reuters2026/07/30 10:25

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cytokinetics secured UK MHRA marketing authorization for MYQORZO (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in eligible adults.
NICE issued positive guidance recommending aficamten for eligible adult patients in England and Wales, supporting NHS use under a commercial arrangement.
Authorization was backed by Phase 3 SEQUOIA-HCM data showing a 1.7 mL/kg/min improvement in peak oxygen uptake versus placebo at 24 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cytokinetics says UK MHRA approves MYQORZO for obstructive hypertrophic cardiomyopathy

You may also like

Crypto prices